4 Insights on decentralized trials for biotechs
The COVID-19 pandemic accelerated the adoption of decentralized clinical trials (DCTs) by biopharma companies. The clinician-patient relationship will always be key to clinical trials, but decentralized aspects such as direct-to-patient shipments and telehealth are here to stay. Here are four things we have learned about DCTs that biotech companies can consider when designing a decentralized or hybrid trial.
Related Insights
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
Podcast
Enabling Successful Sites, Episode 3: Taking the complexity out of oncology clinical trials
Jun 28, 2024
Podcast
Enabling Successful Sites, Episode 2: Empowering Sites to be More Inclusive Through Cultural Sensitivity Training
Jun 28, 2024
Blog
Scientific Advances: Catalyst for Biotech Investment and Innovation in Clinical Development
Mar 12, 2024
Playbook
Insights from the 2022 R&D Innovation Survey
Feb 17, 2023
Blog
Master Protocol Trials: What Are the Elements of Success?
Dec 1, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Blog
Decentralized Trials: Considerations for Building a New Patient-Centric Model
May 13, 2021
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
Article
Reading current FDA and NMPA trends: What oncology tells us about the changing regulatory landscape
Jul 21, 2026
Related Insights
CTB Blog
Modernizing data operations to enable today's Phase 1 trials
Jul 1, 2026
Podcast
Enabling Successful Sites, Episode 3: Taking the complexity out of oncology clinical trials
Jun 28, 2024
Podcast
Enabling Successful Sites, Episode 2: Empowering Sites to be More Inclusive Through Cultural Sensitivity Training
Jun 28, 2024
Blog
Scientific Advances: Catalyst for Biotech Investment and Innovation in Clinical Development
Mar 12, 2024
Playbook
Insights from the 2022 R&D Innovation Survey
Feb 17, 2023
Blog
Master Protocol Trials: What Are the Elements of Success?
Dec 1, 2021
Article
How a joined-up development strategy pays off for early-stage biotechs
May 19, 2021
Blog
Decentralized Trials: Considerations for Building a New Patient-Centric Model
May 13, 2021
CTB Blog
EMA’s new pre-submission interactions model pilot: A fundamental shift toward submission readiness and predictable reviews
Sep 30, 2026
CTB Blog
Engage early, design once: turning early-phase trials into a program strategy
Sep 10, 2026
CTB Blog
Five Practical Strategies for Accelerating Early Phase Studies
Aug 19, 2026
Article
Reading current FDA and NMPA trends: What oncology tells us about the changing regulatory landscape
Jul 21, 2026